
Intellia Therapeutics, Inc.: shareholders and insiders
Price
$9.77
November 18, 2026Market cap $1.4B
What Ploutos Investor adds for Intellia Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 3, 2026, from their own Form 4 filings.
Bought on the market
$1.4M
1 person
Sold on the market
$2.3M
7 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan58%
- The rest42%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $1.4M by 1 person·sold $1.4M by 7 people
- 2025: no buys, sold $836.4K by 1 person
- 2026: bought $1.4M by 1 person, sold $1.4M by 7 people
- Nov 2, 2026John M LeonardPresident and CEOKind10b5-1
- Oct 26, 2026Jing L. MarantzEVP, Chief Medical OfficerKind
- Oct 2, 2026Michael P DubeVP, Chief Accounting OfficerKind
- Aug 21, 2026John M LeonardPresident and CEOKind10b5-1
- Aug 20, 2026John M LeonardPresident and CEOKind10b5-1
- Jul 22, 2026Edward J Dulac IIIEVP, Chief Financial OfficerKind
- Jul 2, 2026Edward J Dulac IIIEVP, Chief Financial OfficerKind10b5-1
- Jul 1, 2026Michael P DubeVP, Chief Accounting OfficerKind
- Jun 9, 2026Frank VerwielDirectorKind
- Jun 9, 2026Georgia KerestyDirectorKind
- Jun 9, 2026Jesse GoodmanDirectorKind
- Jun 9, 2026Brian GoffDirectorKind
- Jun 9, 2026Fred E CohenDirectorKind
- Jun 9, 2026William J ChaseDirectorKind
- Jun 9, 2026Muna BhanjiDirectorKind
- Mar 2, 2026Eliana ClarkEVP, Chief Technical OfficerKind
- Mar 2, 2026James BastaEVP, General CounselKind
- Jan 5, 2026Fred E CohenKind
- Jan 5, 2026Michael P DubeVP, Chief Accounting OfficerKind
- Jan 5, 2026Edward J Dulac IIIEVP, Chief Financial OfficerKind
- Jan 5, 2026Eliana ClarkEVP, Chief Technical OfficerKind
- Jan 5, 2026David LebwohlEVP, Chief Medical OfficerKind
- Jan 5, 2026James BastaEVP, General CounselKind
- Jan 5, 2026Birgit C SchultesEVP, Chief Scientific OfficerKind
- Jan 5, 2026John M LeonardPresident and CEOKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | John M LeonardPresident and CEO | 10b5-1 | 9,000 | $11.99 | $107.9K | Form 4 |
| Oct 26, 2026 | Jing L. MarantzEVP, Chief Medical Officer | 199.8K | – | – | Form 4 | |
| Oct 2, 2026 | Michael P DubeVP, Chief Accounting Officer | 1,864 | $12.43 | $23.2K | Form 4 | |
| Aug 21, 2026 | John M LeonardPresident and CEO | 10b5-1 | 2,785 | $13.00 | $36.2K | Form 4 |
| Aug 20, 2026 | John M LeonardPresident and CEO | 10b5-1 | 19.9K | $12.60 | $250.6K | Form 4 |
| Jul 22, 2026 | Edward J Dulac IIIEVP, Chief Financial Officer | 8,111 | $11.25 | $91.2K | Form 4 | |
| Jul 2, 2026 | Edward J Dulac IIIEVP, Chief Financial Officer | 10b5-1 | 4,677 | $18.00 | $84.2K | Form 4 |
| Jul 1, 2026 | Michael P DubeVP, Chief Accounting Officer | 2,641 | $16.78 | $44.3K | Form 4 | |
| Jun 9, 2026 | Frank VerwielDirector | 9,200 | – | – | Form 4 | |
| Jun 9, 2026 | Georgia KerestyDirector | 9,200 | – | – | Form 4 | |
| Jun 9, 2026 | Jesse GoodmanDirector | 9,200 | – | – | Form 4 | |
| Jun 9, 2026 | Brian GoffDirector | 9,200 | – | – | Form 4 | |
| Jun 9, 2026 | Fred E CohenDirector | 9,200 | – | – | Form 4 | |
| Jun 9, 2026 | William J ChaseDirector | 9,200 | – | – | Form 4 | |
| Jun 9, 2026 | Muna BhanjiDirector | 9,200 | – | – | Form 4 | |
| Mar 2, 2026 | Eliana ClarkEVP, Chief Technical Officer | 607 | $13.78 | $8.4K | Form 4 | |
| Mar 2, 2026 | James BastaEVP, General Counsel | 1,211 | $13.78 | $16.7K | Form 4 | |
| Jan 5, 2026 | Fred E Cohen | 150.0K | $9.35 | $1.4M | Form 4 | |
| Jan 5, 2026 | Michael P DubeVP, Chief Accounting Officer | 2,989 | $9.21 | $27.5K | Form 4 | |
| Jan 5, 2026 | Edward J Dulac IIIEVP, Chief Financial Officer | 6,379 | $9.21 | $58.8K | Form 4 | |
| Jan 5, 2026 | Eliana ClarkEVP, Chief Technical Officer | 9,515 | $9.21 | $87.6K | Form 4 | |
| Jan 5, 2026 | David LebwohlEVP, Chief Medical Officer | 11.9K | $9.21 | $109.6K | Form 4 | |
| Jan 5, 2026 | James BastaEVP, General Counsel | 10.4K | $9.21 | $95.8K | Form 4 | |
| Jan 5, 2026 | Birgit C SchultesEVP, Chief Scientific Officer | 8,508 | $9.21 | $78.4K | Form 4 | |
| Jan 5, 2026 | John M LeonardPresident and CEO | 34.1K | $9.21 | $314.5K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 10, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by NTLA's officers and directors from 2016 up to November 18, 2025, 10 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 5 more, back to 2016
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- ARK Investment Management LLCwith 1 more personShare of class12.3%
- BlackRock, Inc.Share of class8.20%
- State StreetShare of class5.60%
- Vanguard Portfolio ManagementShare of class5.30%
- Vanguard Capital ManagementShare of class5.03%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| ARK Investment Management LLCwith 1 more person | 12.3% | 14.21M | Feb 3, 20262 filings since Nov 4, 2025 | 13G/A | |
| BlackRock, Inc. | 8.20% | 8.45M | Apr 17, 2025 | 13G/A | |
| State Street | 5.60% | 7.81M | Nov 10, 20264 filings since May 13, 2025 | 13G | |
| Vanguard Portfolio Management | 5.30% | 6.27M | Apr 29, 2026 | 13G | |
| Vanguard Capital Management | 5.03% | 5.95M | Apr 30, 2026 | 13G |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- D.E. ShawIn the quarter-5.9%
- Bridgewater (Dalio)In the quarter
- Point72 (Cohen)In the quarter
- Renaissance TechnologiesIn the quarter-58%
- Citadel Advisors (Griffin)In the quarter-22%
- Millennium Mgmt (Englander)In the quarter-79%
- AQR CapitalIn the quarter-29%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| D.E. Shaw | 6.06M | -5.9% | $73M | 0.05% |
| Bridgewater (Dalio) | 137.2K | $1.7M | 0.01% | |
| Point72 (Cohen) | – | – | 0.01% | |
| Renaissance Technologies | 591.2K | -58% | $7.1M | 0.01% |
| Citadel Advisors (Griffin) | 128.0K | -22% | $1.5M | 0.00% |
| Millennium Mgmt (Englander) | 102.1K | -79% | $1.2M | 0.00% |
| AQR Capital | 351.5K | -29% | $4.2M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 31.7% of its shares outstanding were held short, -1.5% since the report before.
- Shares held short
- 44.44M
- 31.7%
- Since the report before45.11M on Sep 30, 2026
- -1.5%
- 6.5
- 6.89M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 74%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 9.63M
- Nov 15, 2023: Shares held short 9.47M
- Nov 30, 2023: Shares held short 9.85M
- Dec 15, 2023: Shares held short 10.50M
- Dec 29, 2023: Shares held short 10.16M
- Jan 12, 2024: Shares held short 10.45M
- Jan 31, 2024: Shares held short 10.97M
- Feb 15, 2024: Shares held short 11.63M
- Feb 29, 2024: Shares held short 12.62M
- Mar 15, 2024: Shares held short 13.50M
- Mar 28, 2024: Shares held short 14.83M
- Apr 15, 2024: Shares held short 14.59M
- Apr 30, 2024: Shares held short 15.44M
- May 15, 2024: Shares held short 15.17M
- May 31, 2024: Shares held short 14.70M
- Jun 14, 2024: Shares held short 13.74M
- Jun 28, 2024: Shares held short 13.25M
- Jul 15, 2024: Shares held short 13.85M
- Jul 31, 2024: Shares held short 13.37M
- Aug 15, 2024: Shares held short 13.82M
- Aug 30, 2024: Shares held short 13.70M
- Sep 13, 2024: Shares held short 14.76M
- Sep 30, 2024: Shares held short 15.14M
- Oct 15, 2024: Shares held short 16.36M
- Oct 31, 2024: Shares held short 16.15M
- Nov 15, 2024: Shares held short 16.37M
- Nov 29, 2024: Shares held short 18.91M
- Dec 13, 2024: Shares held short 19.81M
- Dec 31, 2024: Shares held short 21.67M
- Jan 15, 2025: Shares held short 24.06M
- Jan 31, 2025: Shares held short 24.06M
- Feb 14, 2025: Shares held short 24.42M
- Feb 28, 2025: Shares held short 26.04M
- Mar 14, 2025: Shares held short 26.69M
- Mar 31, 2025: Shares held short 26.94M
- Apr 15, 2025: Shares held short 28.51M
- Apr 30, 2025: Shares held short 28.75M
- May 15, 2025: Shares held short 30.70M
- May 30, 2025: Shares held short 31.56M
- Jun 13, 2025: Shares held short 29.69M
- Jun 30, 2025: Shares held short 30.13M
- Jul 15, 2025: Shares held short 28.87M
- Jul 31, 2025: Shares held short 29.71M
- Aug 15, 2025: Shares held short 27.73M
- Aug 29, 2025: Shares held short 27.74M
- Sep 15, 2025: Shares held short 34.14M
- Sep 30, 2025: Shares held short 29.74M
- Oct 15, 2025: Shares held short 30.90M
- Oct 31, 2025: Shares held short 39.08M
- Nov 14, 2025: Shares held short 40.24M
- Nov 28, 2025: Shares held short 44.57M
- Dec 15, 2025: Shares held short 40.58M
- Dec 31, 2025: Shares held short 41.57M
- Jan 15, 2026: Shares held short 42.56M
- Jan 30, 2026: Shares held short 45.32M
- Feb 13, 2026: Shares held short 45.26M
- Feb 27, 2026: Shares held short 44.31M
- Mar 13, 2026: Shares held short 39.44M
- Mar 31, 2026: Shares held short 38.95M
- Apr 15, 2026: Shares held short 38.81M
- Apr 30, 2026: Shares held short 43.53M
- May 15, 2026: Shares held short 51.85M
- May 29, 2026: Shares held short 48.52M
- Jun 15, 2026: Shares held short 50.32M
- Jun 30, 2026: Shares held short 49.22M
- Jul 15, 2026: Shares held short 45.78M
- Jul 31, 2026: Shares held short 44.01M
- Aug 14, 2026: Shares held short 44.88M
- Aug 31, 2026: Shares held short 43.93M
- Sep 15, 2026: Shares held short 46.68M
- Sep 30, 2026: Shares held short 45.11M
- Oct 15, 2026: Shares held short 44.44M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading53.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 53.4% of the shares in the reported trades were short sales, against 44.0% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 53.4%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 44.0%
- Change
- +9.4 pts
- Short sales a dayon average, of 1.86M shares
- 991.4K
- More than atof 3,656 US-listed companies, same days
- 61%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 48.2%
- Oct 13, 2026: Short sales 50.2%
- Oct 14, 2026: Short sales 52.3%
- Oct 15, 2026: Short sales 48.8%
- Oct 16, 2026: Short sales 41.4%
- Oct 19, 2026: Short sales 54.1%
- Oct 20, 2026: Short sales 40.1%
- Oct 21, 2026: Short sales 46.9%
- Oct 22, 2026: Short sales 37.5%
- Oct 23, 2026: Short sales 42.1%
- Oct 26, 2026: Short sales 49.8%
- Oct 27, 2026: Short sales 28%
- Oct 28, 2026: Short sales 37.1%
- Oct 29, 2026: Short sales 37.3%
- Oct 30, 2026: Short sales 51.1%
- Nov 2, 2026: Short sales 52.6%
- Nov 3, 2026: Short sales 41.8%
- Nov 4, 2026: Short sales 47.9%
- Nov 5, 2026: Short sales 55%
- Nov 6, 2026: Short sales 40.8%
- Nov 9, 2026: Short sales 45.6%
- Nov 10, 2026: Short sales 52.6%
- Nov 11, 2026: Short sales 42.1%
- Nov 12, 2026: Short sales 53.8%
- Nov 13, 2026: Short sales 69.8%
- Nov 16, 2026: Short sales 56.2%
- Nov 17, 2026: Short sales 57.2%
- Nov 18, 2026: Short sales 52.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- John M LeonardPresident and CEODirectly1.20M
- Fred E CohenDirectorDirectly216.7K
- Jing L. MarantzEVP, Chief Medical OfficerDirectly199.8K
- James BastaEVP, General CounselDirectly156.8K
- Edward J Dulac IIIEVP, Chief Financial OfficerDirectly148.2K
- William J ChaseDirectorDirectly143.9K
- David LebwohlEVP, Chief Medical OfficerDirectly121.2K
- Birgit C SchultesEVP, Chief Scientific OfficerDirectly98.5K
- Eliana ClarkEVP, Chief Technical OfficerDirectly93.9K
- Laura Sepp-LorenzinoEVP, Chief Scientific OfficerDirectly77.4K
- Michael P DubeVP, Chief Accounting OfficerDirectly65.0K
- Derek HicksEVP, Chief Business OfficerDirectly59.9K
- Georgia KerestyDirectorDirectly41.1K
- Glenn GoddardEVP, Chief Financial OfficerDirectly40.6K
- Muna BhanjiDirectorDirectly36.4K
- Frank VerwielDirectorDirectly35.1K
- Jesse GoodmanDirectorDirectly33.6K
- Brian GoffDirectorDirectly32.6K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| John M LeonardPresident and CEO | 1.20M | – | Nov 2, 2026 | Form 4 |
| Fred E CohenDirector | 216.7K | – | Jun 9, 2026 | Form 4 |
| Jing L. MarantzEVP, Chief Medical Officer | 199.8K | – | Oct 26, 2026 | Form 4 |
| James BastaEVP, General Counsel | 156.8K | – | Mar 2, 2026 | Form 4 |
| Edward J Dulac IIIEVP, Chief Financial Officer | 148.2K | – | Jul 22, 2026 | Form 4 |
| William J ChaseDirector | 143.9K | – | Jun 9, 2026 | Form 4 |
| David LebwohlEVP, Chief Medical Officer | 121.2K | – | Jan 5, 2026 | Form 4 |
| Birgit C SchultesEVP, Chief Scientific Officer | 98.5K | – | Jan 5, 2026 | Form 4 |
| Eliana ClarkEVP, Chief Technical Officer | 93.9K | – | Mar 2, 2026 | Form 4 |
| Laura Sepp-LorenzinoEVP, Chief Scientific Officer | 77.4K | – | Jan 3, 2025 | Form 4 |
| Michael P DubeVP, Chief Accounting Officer | 65.0K | – | Oct 2, 2026 | Form 4 |
| Derek HicksEVP, Chief Business Officer | 59.9K | – | Jan 3, 2025 | Form 4 |
| Georgia KerestyDirector | 41.1K | – | Jun 9, 2026 | Form 4 |
| Glenn GoddardEVP, Chief Financial Officer | 40.6K | – | Jan 3, 2024 | Form 4 |
| Muna BhanjiDirector | 36.4K | – | Jun 9, 2026 | Form 4 |
| Frank VerwielDirector | 35.1K | – | Jun 9, 2026 | Form 4 |
| Jesse GoodmanDirector | 33.6K | – | Jun 9, 2026 | Form 4 |
| Brian GoffDirector | 32.6K | – | Jun 9, 2026 | Form 4 |
A lower bound: it counts only the 18 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- ARKKARK Innovation ETFWeight in the fund1.92%
- ARKGARK Genomic Revolution ETFWeight in the fund1.83%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.91%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.42%
- IBBiShares Biotechnology ETFWeight in the fund0.17%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.15%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.10%
- IWMiShares Russell 2000 ETFWeight in the fund0.07%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.06%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.05%
23 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 285
- Q4 2025: Managers 293
- Q1 2026: Managers 306
- Q2 2026: Managers 328
Institutional investors by quarter
The fund managers holding NTLA, quarter by quarter, from Q1 2016 to Q2 2025, 38 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 328 managers held 144M shares, worth $2.4B. During the quarter 55 opened a position, 33 closed one, 134 added and 81 trimmed.
The largest holders, Q2 2026
- ARK Investment ManagementIn the quarter+16%
- BlackRockIn the quarter+27%
- State StreetIn the quarter+33%
- Vanguard Portfolio ManagementIn the quarter+18%
- D.E. ShawIn the quarter+12%
- Vanguard Capital ManagementIn the quarter+19%
- Two Sigma InvestmentsIn the quarter+11%
- FMRIn the quarter+131%
- Ra Capital ManagementIn the quarter
- Regeneron PharmaceuticalsIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| ARK Investment Management | 16.88M | +16% | $286M |
| BlackRock | 15.41M | +27% | $261M |
| State Street | 9.23M | +33% | $156M |
| Vanguard Portfolio Management | 7.33M | +18% | $124M |
| D.E. Shaw | 6.44M | +12% | $109M |
| Vanguard Capital Management | 6.03M | +19% | $102M |
| Two Sigma Investments | 5.24M | +11% | $89M |
| FMR | 4.77M | +131% | $81M |
| Ra Capital Management | 4.53M | $77M | |
| Regeneron Pharmaceuticals | 3.70M | $63M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Intellia Therapeutics's filings show?
Who buys and sells is one part of Intellia Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have NTLA's insiders bought or sold?
From Jun 10, 2026 to Nov 3, 2026 Intellia Therapeutics's insiders bought 0 and sold $637.6K of shares on the market. 75% of the sales were under set 10b5-1 plans.
Which well-known managers hold NTLA?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $73M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.